CCM
AXDX

Covington Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Covington Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$0 Buy
+18
New +$298 ﹤0.01% 1189

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Covington Capital Management's AXDX Position: Q3 2022 in Review

Covington Capital Management opened a new position in Accelerate Diagnostics (AXDX) in Q3 2022: 18 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1189 among its holdings.

84 funds tracked by Wall St. Rank hold AXDX as of Q3 2022.

  • Covington Capital Management held 18 shares of Accelerate Diagnostics worth $0 as of Q3 2022.
  • Accelerate Diagnostics was a new Covington Capital Management position in Q3 2022.
  • Accelerate Diagnostics made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #1189 holding.
  • 84 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.